A year ago, Moderna was the most shorted stock in the S&P 500. Today, it is the index’s second-best performer YTD, up 491%.

If its personalized mRNA platform can successfully treat multiple types of cancer, not just melanoma, its current $70 billion market cap may not be the ceiling.